| Exalys Launches With $15M to Treat Postoperative Delirium & More | Sarah de Crescenzo | 07/17/20 | San Diego |
| Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End | Ben Fidler | 10/19/18 | National |
| Adynxx Agrees to Merger with Alliqua to Gain Public Stock Listing | Frank Vinluan | 10/12/18 | San Francisco |
| Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts | Ben Fidler | 04/13/18 | National |
| Despite Pain Drug’s Mid-Stage Miss, Adynxx Plans a Larger Phase 3 Test | Frank Vinluan | 04/12/18 | San Francisco |
| Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More | Ben Fidler | 01/13/17 | National |
| Pain Drug Developer Adynxx Picks Up $16M for Another Clinical Trial | Frank Vinluan | 01/10/17 | San Francisco |
| Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out | Ben Fidler | 08/08/16 | Boston |
| West Coast Biotech Roundup: Global Blood, Invitae, GeneWEAVE, Adynxx | Alex Lash | 08/13/15 | San Francisco |
| Built for a Deal, Annovation Rewards Backers With Medicines Co. Buyout | Ben Fidler | 02/04/15 | Boston |
| East Coast Biotech Roundup: JP Morgan Edition | Ben Fidler | 01/17/14 | Boston |
| Biotech VCs Aren’t Lemmings Anymore. They’re Lone Rangers | Luke Timmerman | 03/25/13 | National |
| East Coast Life Sciences Roundup: Third Rock, SciFluor, Cubist | Bernadette Tansey | 03/01/13 | Boston |
| Cubist Pharmaceuticals Acquires Adynxx for Undisclosed Sum | VentureDeal | 02/25/13 | San Francisco |
| Adynxx Obtains $4,803,858 Series A Round | VentureDeal | 12/27/10 | San Francisco |
